NEO100-01
- Indication
- Malignant recurrent WHO Grade 3 /4 IDH1 Astrocytoma
- Stage
- phase2
- Event
- Topline Data
- Details
Aug. 10, 2026: NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) announced an investor conference call/webcast for Aug. 12, 2026, at 8:30 a.m. ET to present topline results from the Phase 2a portion of the NEO100-01 trial.
The catalyst is an upcoming clinical data presentation for NEO100, an intranasal formulation of purified perillyl alcohol, in an open-label study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company said the discussion will cover efficacy and safety observations from Phase 2a and planned regulatory next steps, followed by Q&A.
The release does not disclose the actual topline data or outcomes. It also states that NEO100 and NEO212 are in Phase II trials and are advancing under FDA Fast-Track and IND status.
- Source
- View catalyst source ↗